ML-262 is primarily utilized in research settings as a potent and selective inhibitor of the enzyme N-acylethanolamine acid amidase (NAAA). This enzyme plays a significant role in the breakdown of endogenous fatty acid ethanolamides, such as palmitoylethanolamide (PEA), which are involved in regulating inflammation and pain. By inhibiting NAAA, ML-262 helps to increase the levels of these bioactive lipids, providing a potential therapeutic approach for managing inflammatory and neuropathic pain conditions. Its application is particularly relevant in preclinical studies aimed at understanding the mechanisms of pain and inflammation, as well as in the development of novel anti-inflammatory and analgesic drugs. Researchers also explore its potential in treating chronic inflammatory diseases, where modulating NAAA activity could offer significant benefits.